A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial
| Autor: | Américo Figueiredo, Joar Austad, Yves Poulin, Jean-Paul Ortonne, Cecilia Ganslandt, A. David Burden, Berit Berne, Pablo de Unamuno, Gregor B.E. Jemec |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Anti-Inflammatory Agents Betamethasone dipropionate Dermatology Administration Cutaneous Betamethasone Severity of Illness Index law.invention chemistry.chemical_compound Calcitriol Double-Blind Method Randomized controlled trial law Psoriasis medicine Humans Calcipotriol Aged Skin Aged 80 and over business.industry Middle Aged medicine.disease Drug Combinations Treatment Outcome medicine.anatomical_structure Scalp Dermatoses chemistry Scalp Calcipotriene Corticosteroid Female Dermatologic Agents Pharmaceutical Vehicles business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 59:455-463 |
| ISSN: | 0190-9622 |
| Popis: | Background New topical treatments in scalp psoriasis are needed because many current topical treatments are disliked by patients and associated with poor compliance. Objective To compare the efficacy and safety of once-daily, two-compound scalp formulation containing calcipotriene plus betamethasone dipropionate with the individual components in the same vehicle and the vehicle alone. Methods In this 8-week, multicenter, randomized, double-blind study, patients with scalp psoriasis were randomized to treatment with the two-compound scalp formulation (calcipotriene 50 μg/g plus betamethasone 0.5 mg/g, as dipropionate) (n = 541), betamethasone 0.5 mg/g (as dipropionate) in the same vehicle (n = 556), calcipotriene 50 μg/g in the same vehicle (n = 272), or vehicle alone (n = 136). Results More patients achieved "absent" or "very mild" disease at week 8 with the two-compound scalp formulation (71.2%) compared with betamethasone dipropionate in the same vehicle (64.0%, p = .011), calcipotriene in the same vehicle (36.8%, p p Limitations Efficacy of the active comparators in the study has not been established in relation to calcipotriene and betamethasone formulations available for clinical use. Conclusion Calcipotriene plus betamethasone dipropionate scalp formulation was more effective than either of the individual components or the vehicle alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect